The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

AHA letter to the Health Resources and Services Administration about a new concerning development with the 340B Program.

A new chapter in the 340B Drug Pricing Program is unfolding as the Health Resources & Services Administration (“HRSA”) pursues its 340B Rebate Model Pilot Program (the “Pilot Program”)—a move ...

The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more ...

The Health Resources and Services Administration (HRSA) issued a notice announcing the application process for the 340B rebate model pilot program and requesting public comment. The notice sets the ...

HRSA is piloting a 340B rebate model similar to one that it just fought against. As the agency dips its toes into the 340B debate, hospital groups express concerns about the potential for cash flow ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Federal regulators have greenlit eight drugmaker ...

The AHA March 3 urged the Health Resources and Services Administration to take immediate action to stop a new Novo Nordisk ...

The Health Resources and Services Administration released a proposed rule Thursday, implementing an Affordable Care Act provision that establishes a dispute resolution process for certain 340B Drug ...

The anticipated burdens on hospitals to comply with the Health Resources and Services Administration's 340B Rebate Pilot Program far exceed the agency's estimates, and HRSA should delay the program's ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The Health Resources and Services Administration of HHS has issued a final rule to clarify how the agency will implement the 340B drug discount program orphan drug exclusion for newly eligible ...